| Field | Specification |
|---|---|
| Target | |
| Alternative names | BH3-interacting domain death agonist; p22 BID; BID |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human Bid recombinant protein (Position: M1-D195). Human Bid shares 64% and 61% amino acid (aa) sequences identity with mouse and rat Bid, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 10F4 is a mouse monoclonal antibody that recognizes BH3-interacting domain death agonist (gene BID) in human samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 22.0 kDa, and the supplier reports an observed band at about 22 kDa.
BID is a BH3-only pro-apoptotic Bcl-2 family protein that links death receptor signaling to mitochondria. After cleavage by caspase-8 (or other proteases), truncated BID (tBID) moves to mitochondria and activates BAX and BAK, causing cytochrome c release and amplifying the apoptotic signal.
| Target | BH3-interacting domain death agonist (gene BID; UniProt P55957, human) |
|---|---|
| Clone | 10F4 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2b |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 22.0 kDa |
| Observed MW | 22 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human Jurkat cells, human A549 cells, human HEK293 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human rectal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): MCF-7 cells.
Samples with a confirmed signal (flow cytometry): A549 cells.
Immunogen
Recombinant human Bid fragment (Met1–Asp195), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 64% and 61%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places BH3-interacting domain death agonist in the cytoplasm, mitochondrion membrane and mitochondrion outer membrane. Tissue expression noted by UniProt (human): Expressed in spleen, pancreas and placenta (at protein level)... The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
